907 related articles for article (PubMed ID: 30565265)
1. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
Holko P; Kawalec P; Pilc A
Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
[TBL] [Abstract][Full Text] [Related]
3. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA
J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641
[No Abstract] [Full Text] [Related]
4. Cost-utility analysis of biologic treatments for moderate-to-severe Crohn's disease.
Tang DH; Armstrong EP; Lee JK
Pharmacotherapy; 2012 Jun; 32(6):515-26. PubMed ID: 22528603
[TBL] [Abstract][Full Text] [Related]
5. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Kobayashi T; Hoshi M; Yuasa A; Arai S; Ikeda M; Matsuda H; Kim SW; Hibi T
Pharmacoeconomics; 2023 May; 41(5):589-604. PubMed ID: 36884164
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
Rencz F; Gulácsi L; Péntek M; Gecse KB; Dignass A; Halfvarson J; Gomollón F; Baji P; Peyrin-Biroulet L; Lakatos PL; Brodszky V
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):597-606. PubMed ID: 28434387
[TBL] [Abstract][Full Text] [Related]
9. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.
Yu AP; Johnson S; Wang ST; Atanasov P; Tang J; Wu E; Chao J; Mulani PM
Pharmacoeconomics; 2009; 27(7):609-21. PubMed ID: 19663531
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan.
Hernandez L; Kuwabara H; Shah A; Yamabe K; Burnett H; Fahrbach K; Koufopoulou M; Iwakiri R
Pharmacoeconomics; 2020 Jan; 38(1):69-84. PubMed ID: 31552601
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
12. Simulated cost-effectiveness of a novel precision-guided dosing strategy in adult patients with Crohn's disease initiating infliximab maintenance therapy.
Alizadeh ER; Dervieux T; Vermeire S; Dubinsky M; D'Haens G; Laharie D; Shim A; Vaughn BP
Pharmacotherapy; 2024 Apr; 44(4):331-342. PubMed ID: 38576238
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
Louis E; Litkiewicz M; Agboton C; Armuzzi A
United European Gastroenterol J; 2024 Jun; 12(5):574-584. PubMed ID: 38717013
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting.
Küster D; Nast A; Gerdes S; Weberschock T; Wozel G; Gutknecht M; Schmitt J
Arch Dermatol Res; 2016 May; 308(4):249-61. PubMed ID: 26961372
[TBL] [Abstract][Full Text] [Related]
15. Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.
Beilman CL; Kirwin E; Ma C; McCabe C; Fedorak RN; Halloran B
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1515-1524.e4. PubMed ID: 30056180
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn's disease using real world evidence in Thailand.
Phisalprapa P; Kositamongkol C; Limsrivilai J; Aniwan S; Charatcharoenwitthaya P; Pisespongsa P; Kitiyakara T; Treepongkaruna S; Chaiyakunapruk N
J Med Econ; 2020 Nov; 23(11):1302-1310. PubMed ID: 32729347
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
[TBL] [Abstract][Full Text] [Related]
19. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
Singh S; Fumery M; Sandborn WJ; Murad MH
Aliment Pharmacol Ther; 2018 Aug; 48(4):394-409. PubMed ID: 29920733
[TBL] [Abstract][Full Text] [Related]
20. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
